This unique dual formulation provides the potential benefit for smooth transition from short-term intravenous to long-term oral antiplatelet therapy. It has a plasma half-life of approximately 12 ...

In updated American recommendations for the management of acute coronary syndrome (ACS), bleeding reduction strategies on antiplatelet therapy are embraced, as are non-statin lipid-lowering therapies ...

Ali, H. , Ghaysaa, H. , Jaafar, W. and Malek, M. (2025) Ischemic Stroke Following Coronary Angiography: A Case Report. Case Reports in Clinical Medicine, 14, 123-129. doi: 10.4236/crcm.2025.143016 .

Intravenous. The authors have no relevant ... It is questionable whether individualized antiplatelet therapy should be based on genetic testing, platelet function testing or both.